Akademik Veri Yönetim Sistemi
Bratislava Medical Journal, cilt.116, sa.2, ss.124-127, 2015 (SCI-Expanded, Scopus)
Introduction: Our aim was to determine the efficacy of trimetazidine on experimental sepsis rat model. Material and methods: Sixty rats were randomized into three groups. In Group 1, sepsis was induced. In Group 2, sepsis was induced and as a therapeutic agent trimetazidine was given. In Group 3, rats were sham operated. Serum interleukin-1 beta (IL-1ß), tumor necrosis factor alfa (TNF-α), superoxide dismutase (SOD), glutathion peroxidase (GSH-Px) and malondialdehyde (MDA) levels were determined in all groups. Results: In Group 2, serum GSH-Px and SOD levels were statistically significantly higher than in Group 1 (p < 0.05) and serum MDA levels were statistically significantly lower than in group 1 (p < 0.05). Trimetazidine also significantly decreased the levels of IL-1ß and TNF-a which are the proinflammatory cytokines (p < 0.05). Conclusion: Trimetazidine treatment significantly improved inflammation, oxidative stress and membrane destruction in LPS-induced sepsis. As the proinflammatory cytokines are supposed to play a primary role in the pathogenesis of sepsis, we assumed that the trimetazidine treatment would give new insights into the treatment of sepsis.